FDA Warns Drugmaker on Postmarket Paperwork Problems

Drug Industry Daily
A A
A New Jersey drugmaker was warned by the FDA for failing to submit paperwork on possible adverse drug experiences for their products.

To View This Article:

Login

Subscribe To Drug Industry Daily